<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The natural history of <z:hpo ids='HP_0004818'>paroxysmal nocturnal hemoglobinuria</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PNH</z:e>) clinical subcategories (classic <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PNH</z:e> and <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> [AA]/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PNH</z:e> syndrome) is still unknown </plain></SENT>
<SENT sid="1" pm="."><plain>We retrospectively studied 460 PNH patients diagnosed in 58 French hematologic centers from 1950 to 2005 </plain></SENT>
<SENT sid="2" pm="."><plain>The median (SE) follow-up time was 6.8 (0.5) years </plain></SENT>
<SENT sid="3" pm="."><plain>The median survival time (SE) was 22 (2.5) years </plain></SENT>
<SENT sid="4" pm="."><plain>We identified 113 patients with classic <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PNH</z:e>, 224 patients with AA-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PNH</z:e> syndrome, and 93 (22%) intermediate patients who did not fit within these 2 categories </plain></SENT>
<SENT sid="5" pm="."><plain>At presentation, classic <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PNH</z:e> patients were older, with more frequent <z:hpo ids='HP_0002027'>abdominal pain</z:hpo> and displayed higher levels of GPI-AP-deficient granulocytes </plain></SENT>
<SENT sid="6" pm="."><plain>A time-dependent improved survival was observed </plain></SENT>
<SENT sid="7" pm="."><plain>In classic <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PNH</z:e>, diagnoses before 1986 (hazard ratio [HR]: 3.6; P = .01) and increasing age (P &lt; .001) were associated with worse survival prognoses, whereas use of <z:chebi fb="5" ids="50113">androgens</z:chebi> within the first year after diagnosis was protective (HR, 0.17; P = .01) </plain></SENT>
<SENT sid="8" pm="."><plain>Transfusions before 1996 (HR, 2.7; P = .007) led to lower survival rates in patients with AA-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PNH</z:e> syndrome, whereas immunosuppressive treatment was associated with better outcomes (HR, 0.33; P = .03) </plain></SENT>
<SENT sid="9" pm="."><plain>Evolution to <z:mp ids='MP_0005048'>thrombosis</z:mp> affected survival in both subcategories (classic <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PNH</z:e>: HR, 7.8 [P &lt; .001]; AA-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PNH</z:e> syndrome: HR, 33.0 [P &lt; .001]) </plain></SENT>
<SENT sid="10" pm="."><plain>Evolution to bicytopenia or <z:hpo ids='HP_0001876'>pancytopenia</z:hpo> for classic <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PNH</z:e> (HR, 7.3, P &lt; .001) and <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> for AA-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PNH</z:e> syndrome (HR, 48.8; P &lt; .001) were associated with worse outcomes </plain></SENT>
<SENT sid="11" pm="."><plain>Although clinical presentation and prognosis factors are different, classic <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PNH</z:e> and AA-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PNH</z:e> syndrome present roughly similar outcomes, affected mainly by complications </plain></SENT>
</text></document>